Trial Profile

A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HX 009 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Waterstone Hanxbio

Most Recent Events

08 Dec 2022 Status changed from active, no longer recruiting to completed.
07 Jul 2021 Status changed from recruiting to active, no longer recruiting.
08 Jun 2021 Preliminary results (data cutoff date: 22 Jan 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com